Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR AMPLIFICATION ( ENST00000275493.7 )
EGFR AMPLIFICATION ( ENST00000275493.7 )
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
In 290 patients with advanced NSCLC, 177 of which were treated with EGFR TKI (erlotinib or gefitinib). EGFR amplification (Multiplex ligation-dependent probe amplification; MLPA) and Mutation (PCR) were analzed. EGFR amplification was associated with EGFR mutation but not independently with patient benefit from EGFR TKI (overall and progression-free survival).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/977
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/190
Rating
2
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Does Not Support
Drug
Erlotinib,Gefitinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26722081
Drugs
Drug NameSensitivitySupported
ErlotinibSensitivityfalse
GefitinibSensitivityfalse